Compare GSK plc (GSK) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Palantir Technologies Inc — how do they compare? GSK plc trades at $50.24 (market cap $102.60B), while Palantir Technologies Inc trades at $170.94 (market cap $420.39B). The key difference: Palantir Technologies Inc is far larger — about 4.1× GSK plc's market cap, and GSK plc pays a 3.57% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| GSK | PLTR | |
|---|---|---|
Market Cap | $102.60B | $420.39B |
Sector | Health | Technology |
52-Week High | $61.18 | $207.18 |
52-Week Low | $38.22 | $107.27 |
Enterprise Value | $123.04B | $411.19B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Palantir (PLTR) trades at $175.20, up 1.85% with strong bullish technical signals and consistent earnings beats. The stock shows impressive fundamental growth with revenue reaching $4.48 billion in 2025 and net income margin expanding to 36.3%. Recent quarterly EPS results have exceeded expectations, driving positive investor sentiment despite elevated valuation multiples. Technical indicators show bullish momentum with the current price near pivot point resistance at $175.
Outlook remains positive with accelerating revenue growth and expanding margins, though high valuation ratios (P/E 149.52, P/S 73.07) present risk. Analyst consensus targets $213.44 with 50% buy ratings, but insider selling and Michael Burry's bearish stance highlight caution. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in the AI software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
